Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) CEO Sells 442,935 Shares of Stock

Key Points

• CEO Richard Francis sold 442,935 shares (~41% of his position) at an average of $32.36 for about $14.33M, leaving him with 642,099 shares — a large insider disposition that coincided with a roughly 3.6% drop in the stock.
• Teva posted a strong quarter, beating expectations with $0.96 EPS (vs. $0.65) and $4.71B revenue (vs. $4.36B), set FY2026 guidance of 2.570–2.770 EPS, and drew multiple analyst price-target upgrades (consensus target ~$37.67).
• Blackstone Life Sciences agreed to provide $400M to advance Teva’s Phase‑3 antibody duvakitug, supplying non-dilutive capital that de-risks development funding and supports Teva’s shift toward specialty assets.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) CEO Richard Francis sold 442,935 shares of the company's stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $32.36, for a total value of $14,333,376.60. Following the sale, the chief executive officer owned 642,099 shares of the company's stock, valued at approximately $20,778,323.64. The trade was a 40.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Teva Pharmaceutical Industries Stock Down 3.6%

Teva Pharmaceutical Industries stock traded down $1.19 during trading on Thursday, reaching $31.72. 9,925,965 shares of the company's stock were exchanged, compared to its average volume of 9,707,048. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $37.35. The firm has a market cap of $36.47 billion, a price-to-earnings ratio of 26.43, a PEG ratio of 10.80 and a beta of 0.72. The company's 50-day moving average is $33.03 and its two-hundred day moving average is $26.07.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating analysts' consensus estimates of $0.65 by $0.31. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.Teva Pharmaceutical Industries's revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Institutional Trading of Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently made changes to their positions in the business. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries by 19.2% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company's stock worth $1,402,945,000 after purchasing an additional 7,255,083 shares during the period. Phoenix Financial Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 9.4% during the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company's stock valued at $834,164,000 after buying an additional 3,533,800 shares during the period. Menora Mivtachim Holdings LTD. boosted its stake in shares of Teva Pharmaceutical Industries by 1.1% during the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company's stock valued at $786,190,000 after buying an additional 427,000 shares during the period. Clal Insurance Enterprises Holdings Ltd grew its holdings in shares of Teva Pharmaceutical Industries by 18.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company's stock valued at $1,171,378,000 after acquiring an additional 5,917,423 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 14.8% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company's stock worth $1,167,323,000 after acquiring an additional 4,820,000 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Blackstone Life Sciences agreed to provide $400M to advance Teva’s duvakitug (a Phase 3 antibody for ulcerative colitis/Crohn’s). The deal brings non-dilutive capital, de-risks development funding and validates Teva’s pivot toward innovative specialty assets. Teva and Blackstone Life Sciences Announce $400M Strategic Growth Capital Agreement
• Positive Sentiment: Piper Sandler reaffirmed an "overweight" rating and nudged its price target to $41 (from $40), signaling analyst confidence in TEVA’s upside vs. peers. That supports longer-term investor interest despite near-term volatility. Piper Sandler Overweight Rating
• Neutral Sentiment: Sector coverage notes ongoing pricing pressure in generics; Teva is highlighted as pursuing complex generics and biosimilars to offset headwinds — strategy may protect growth but execution risk remains. 3 Generic Drug Stocks to Watch
• Neutral Sentiment: Broader industry coverage on AI adoption in pharma could benefit larger, R&D-focused players over time; not an immediate stock driver but relevant to Teva’s innovation push. Pharma Industry's AI Adoption
• Negative Sentiment: CEO Richard Francis sold 442,935 shares (~41% reduction of his position) at ~$32.36 per share, a large insider disposition that can spook investors even if for personal/portfolio reasons. SEC filing: SEC Filing - Insider Sale
• Negative Sentiment: Notable investor exits: billionaire Stanley Druckenmiller trimmed Teva in recent 13F activity, indicating some large-manager profit-taking or rotation away from the name. Druckenmiller Trimmed Teva
• Negative Sentiment: Opinion pieces suggest income-focused investors may prefer higher-yield competitors, which could siphon dividend-oriented demand from TEVA in the near term. Dividend Comparison Article

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on TEVA shares. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an "overweight" rating in a research note on Friday, January 30th. The Goldman Sachs Group raised their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, February 9th. Truist Financial upped their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a "buy" rating in a research note on Wednesday, February 18th. Scotiabank increased their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a "sector outperform" rating in a report on Thursday, January 29th. Finally, Piper Sandler reiterated an "overweight" rating and set a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and a consensus price target of $37.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.